Analysis of the immune landscape and tumor mutational burden, specifically programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) protein expression, may be useful to assess immunotherapy treatment response related to carcinoid. This evidence concerns the gene CD274 and carcinoid tumor.